Provided by Tiger Trade Technology Pte. Ltd.

Biogen

230.56
+1.150.50%
Volume:50.55K
Turnover:11.64M
Market Cap:34.04B
PE:40.95
High:230.87
Open:230.34
Low:228.53
Close:229.41
52wk High:238.24
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.39
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.81
PE(LYR):26.23

Loading ...

Biogen price target raised to $270 from $240 at UBS

TIPRANKS
·
Oct 09

Biogen Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 09

Biogen Price Target Cut to $256.00/Share from $260.00 by RBC Capital

Dow Jones
·
Oct 08

RBC Cuts Price Target on Biogen to $256 From $260, Keeps Outperform Rating

MT Newswires Live
·
Oct 08

Biogen : RBC Cuts Target Price to $256 from $260

THOMSON REUTERS
·
Oct 08

How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB)

Simply Wall St.
·
Oct 08

Pharma Stocks Rally With Amgen, Gilead Sciences up 3%

Tiger Newspress
·
Oct 07

AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?

TIPRANKS
·
Oct 07

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Oct 07

Biogen Maintained at Buy as Analyst Sees Favorable Risk-Reward Ahead of Lupus Data; $256 Price Target Reaffirmed

TIPRANKS
·
Oct 06

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

Piper Sandler Keeps Their Buy Rating on Biogen (BIIB)

TIPRANKS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Oct 03

Biogen Says Litifilimab Safety Profile Consistent with no New Safety Signals Identified

Reuters
·
Oct 03